Follow us on Twitter
twitter icon@FreshPatents


Cholesterol patents

      

This page is updated frequently with new Cholesterol-related patent applications.




 Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome patent thumbnailCompositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University


 Methods targeting mir-128 for regulating cholesterol/lipid metabolism patent thumbnailMethods targeting mir-128 for regulating cholesterol/lipid metabolism
Methods for targeting microrna 128 (mir-128) for regulating cholesterol/lipid metabolism and insulin sensitivity.. .
The General Hospital Corporation


 Nanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation patent thumbnailNanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation
In one embodiment, the present application discloses synthetic ldl nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin e, and methods for preparing the synthetic nanoparticles. The disclosed synthetic ldl nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing ldl receptors after intra venous injection..
Arbor Therapeutics, Llc


 Liposome composition and  producing same patent thumbnailLiposome composition and producing same
Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase..
Fujifilm Corporation


 Use of cilastatin to reduce the nephrotoxicity of different compounds patent thumbnailUse of cilastatin to reduce the nephrotoxicity of different compounds
Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts.
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon


 Novel 7-dehydrocholesterol derivatives and methods using same patent thumbnailNovel 7-dehydrocholesterol derivatives and methods using same
The present invention provides, in certain aspects, novel 7-dehydrocholesterol (7dhc) derivatives that are useful in treating or preventing cancer, as well as in treating or preventing uncontrolled angiogenesis, in a subject. In certain embodiments of the present invention, the subject is a human.
Women & Infants Hospital Of Rhode Island


 Compositions for the treatment of cataracts patent thumbnailCompositions for the treatment of cataracts
In one embodiment, the present application discloses an aqueous ophthalmic composition for the treatment of eye diseases, lesions and injuries, comprising: a) one steroid, or a combination of at least two steroids selected from the group consisting of lanosterol, dihydrolanosterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol, 4,4-dimethylcholesta-8,24-dien-3β-ol, 4,4-dimethylcholesta-8-en-3β-ol, 4,4-dimethylcholesta-8(9),14-dien-3β-ol, 14-desmethyl lanosterol, lathosterol, Δ7,24-cholestadienol, cholesterol, cholesta-7-enol, cholesteryl ester, 7-dehydrocholesterol, desmosterol, 7-dehydrodesmosterol, zymosterol, 27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-oso3h (5-cholesten-3β,25-sulfate), 5-cholesten-3β-oso3h,25-ol (5-cholesten-3β-sulfate,25-ol), 5-cholesten-3β,25-diol, disulfate, and their esters thereof, or a pharmaceutically acceptable salt thereof, in a concentration effective for the treatment and/or prophylaxis of the eye diseases, lesions and injuries; and b) a pharmaceutical excipient; and methods of treatment using such compositions.. .
Catacore, Inc.


 Use of delta tocopherol for the treatment of lysosomal storage disorders patent thumbnailUse of delta tocopherol for the treatment of lysosomal storage disorders
This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of δ tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders.
The United States Of America, As Represented By Secretary, Dept. Of Health & Human Services


 Control device for a motor vehicle and control method patent thumbnailControl device for a motor vehicle and control method
The present invention relates to a new process for the synthesis of colesevelam, which is used in therapy in cases of hypercholesterolemia due to low density lipoproteins. Said process comprises the reaction, in a basic environment, of polyallylamine with: i) at least one alkylating agent of formula x—(ch2)9—ch3 and at least one alkylating agent of formula y—(ch2)6—n+ (ch3)3z−, wherein x and y are each independently a leaving group, and z is a halogen; and ii) at least one crosslinking agent.
Dav


 Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) patent thumbnailNovel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
Novel forms of [r, (r*,r*)]-2-(4-fluorophenyl)-β,δdihydroxy-5-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, forms xxv, form xxvii, form xxviii, form xxxix, and forms xxx, characterized by their x-ray powder diffractor, solid state nmr, and/or raman spectroscopy are describes as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (bph) and alzheimer) disease.. .
Warner-lambert Company Llc


Novel low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.

Low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.

Uses of oxygenated cholesterol sulfates (ocs)

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (mods), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (ocs), e.g.
Durect Corporation

Anti-cholesterolemic compounds and methods of use

The present invention provides novel compounds with hypocholesteremic activity from crude embilica officinialis (eo) extracts and methods of use. The invention also provides nutraceuticals..

Nasal vaccine for streptococcus pneumoniae

The present invention provides a nasal vaccine for streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of pspa, i.e.
Lsip, Llc

Nutritional composition

A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.. .
Hero Ag

Infusion of insulin into a patient and diabetes mellitus medical methods based on the patients monitored analyte concentration

Medical data provided by a physiological parameter sensor is used for management of the patient's medical condition. Analytes that may be monitored and managed include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., ck-mb), creatine, glucose, glutamine, growth hormones, hormones, ketones, lactate, oxygen, peroxide, prostate-specific antigen, prothrombin, thyroid stimulating hormone, and troponin..
Abbott Diabetes Care Inc.

Method and system for extracting and using moomiyo compositions

A method and system for extraction of moomiyo from a multi-component, naturally-occurring mineral substance generally found in asian mountain ranges at elevations approximately between 1000 and 5000 meters. Bio-active compounds are extracted from said mineral substance for the medicinal applications including at least one of joint pain relief, skin care, anti-inflammation, bruise removal, decrease high blood cholesterol and high triglycerides levels, promotion of mental and physical energy, regulation of blood sugar levels, stimulation of the immune system, speeding of the recovery from sickness and wound healing therapies..

Diether based biodegradable cationic lipids for sirna delivery

Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.

Pegylated 7-dehydrocholesterol derivatives

The present invention relates to pegylated 7-dehydrocholesterol derivatives, and a composition for wrinkle alleviation and anti-aging comprising the same. The pegylated 7-dehydrocholesterol derivatives according to the present invention have improved stability and solubility in water, and thus can be effectively used as a good source for supplying vitamin d in a cosmetic composition, a pharmaceutical composition and a functional food for wrinkle alleviation and anti-aging..
Humedix Co., Ltd.

5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative

A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-hdl-cholesterolemia, hyper-ldl-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein r is an optionally substituted aryl group or an optionally substituted heteroaryl group, and r1 is a hydrogen atom or a hydroxy group.. .
Daiichi Sankyo Company, Limited

Methods of using interleukin-10 for treating diseases and disorders

Methods for determining dosing parameters associated with subcutaneous administration of il-10 useful for the treatment and/or prevention of a cholesterol-related disease, disorder or condition, and pharmaceutical compositions associated therewith, are provided herein. Certain embodiments are directed to means for establishing a therapeutic range of an il-10 agent in a subject.
Armo Biosciences, Inc.

Proliposomal testosterone formulations

Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions.
Tesorx Pharma, Llc

Compositions based on methyl cyclodextrins for the treatment and/or prevention of diseases by increasing the hdl cholesterol level

The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a molar substitution (ms) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be treated and/or prevented by an increase in the hdl cholesterol level. The invention also relates to the use thereof in the treatment and/or prevention of atherosclerosis or complications relating to an atheroma, and/or diseases of the central nervous system.
Roquette Freres

Compounds, compositions and methods useful for cholesterol mobilization

The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein..
Cerenis Therapeutics Holding Sa

Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis

The present invention features methods for preventing and treating three related diseases, diet-induced obesity, metabolic syndrome, and atherosclerosis, alone or in combination by inhibiting acyl-coa: cholesterol acyltransferase 1 (acati) activity or expression in myeloid cells.. .
Trustees Of Dartmouth College

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis

5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virginia Commonwealth University

3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein

3,3′-disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.. .
Merck Sharp & Dohme Corp.

Beta-lactam cholesterol absorption inhibitors

The present invention relates to the novel compounds represented by formula (ia) or (ib) and to their pharmaceutical preparations for the treatment of atherosclerosis and cholesterol level reduction.. .
Rudjer Boskovic Institute

Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelithiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses.

Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellullar senescence produced by diabetis and other degenerative chronic complex diseases

The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of formulation i, and its method on in vitro and in vivo systems.

Compositions and therapeutic methods for accelerated plaque regression

The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through-co-administration of therapeutically effective amounts of a compound of formula i or a pharmaceutically acceptable salt thereof and rosuvastatin or pravastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin. The invention further provides compositions comprising a therapeutically effective amount of a compound of formula i or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of or pitavastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin..
Resverlogix Corp

Use of quaternary pyridinium salts as vasoprotective agents

Wherein r is nh2, ch3, or n(h)ch2oh group, and x is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin pgi2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low hdl level.. .

Endoxifen compositions and methods

The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, z- and e-guggulsterones, phospholipids, fatty acids, vitamin d, and vitamin e.
Jina Pharmaceuticals, Inc.

Ketohexokinase (khk) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the ketohexokinase (khk) gene, and methods of using such rnai agents to inhibit expression of khk and methods of treating subjects having a khk-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high ldl cholesterol, low hdl cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.. .
Alnylam Pharmaceuticals, Inc.

Liposome comprising at least one cholesterol derivative

More particularly the invention relates to liposomes comprising at least one cholesterol derivative and compositions comprising said liposomes.. .

Antidiabetic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Michael Miller

Process for producing 7-dehydrocholesterol and vitamin d3

According to the present invention, there can be provided a process for producing 7-dehydrocholesterol (hereinafter, “7dhc”), comprising culturing, in a medium, a 7dhc-producing labyrinthulea microorganism in which the 7dhc reducing activity is reduced or lost as compared to a parent strain through deletion, substitution, or addition of at least one base in a gene which is present in the chromosomal dna of the parent strain and encodes a protein having 7dhc reducing activity, and the microorganism produces 7dhc, allowing 7dhc to be produced and accumulated in the culture, and collecting the 7dhc from the culture; and a process for producing vitamin d3, comprising irradiating, with ultraviolet light, the 7dhc produced by the production process.. .
Kyowa Hakko Bio Co. Ltd.

Shunting of dietary lipids including cholesterol

Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body.
Boston Scientific Scimed, Inc.

Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects

The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an mtp inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the mtp inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the mtp inhibitor to the subject.
The Trustees Of The University Of Pennsylvania

Cholesterol efflux capacity assessment

A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (cec) value. Methods relate to determining sr-bi-mediated and abca1-mediated cec.
Boston Heart Diagnostics

Cholesterol efflux capacity assessment

A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (cec) level. Methods relate to determining sr-bi-mediated and abca1-mediated cec.
Boston Heart Diagnostics Corporation

Measurement of serum lipoproteins

Although a more accurate estimate of a person's risk of cardiovascular disease can be made on the basis of the number of lipoprotein particles per unit volume in the person's blood, current methods all rely on measuring the mass of lipoprotein cholesterol per unit volume. It has been discovered that a rapid and accurate lipoprotein particle count can be obtained by photometry.
Atherotech, Inc.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.2164

file did exist - 2572

2 - 1 - 52